Welcome to Markets Desk, your midday read on the stories moving markets and the broader business landscape.
Nvidia's board has opened a formal investigation into whether CEO Jensen Huang was the target of a foreign intelligence operation. The company was quick to stress it has no reason to believe any proprietary technology or national security information was compromised, but the probe signals just how seriously the chip giant is treating the matter given its position at the center of global AI competition.
Turning to pharmaceuticals, Novo Nordisk's oral GLP-one weight loss drug Wegovy has now surpassed five million prescriptions, a milestone that underscores the explosive demand for non-injectable obesity treatments. The question investors are wrestling with is whether that commercial momentum is already priced into the stock, or whether the pill format opens a meaningfully larger patient population that the market hasn't fully credited yet.
And on the banking side, analysts have trimmed their price target on China Minsheng Banking's depositary receipt by nearly fourteen percent, bringing the consensus down to four dollars and twenty-one cents from four dollars and eighty-eight cents. The downward revision reflects continued pressure on Chinese financial institutions amid a challenging domestic credit environment and softening macro conditions.
That's the tape. Markets Desk, signing off the floor.
